• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗中高出血风险患者的性别相关差异:4 项批准后研究的患者水平汇总分析。

Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies.

机构信息

The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York NY.

Sorbonne Université ACTION study group INSERM UMR_S 1166 Institut de Cardiologie Hôpital Pitié-Salpêtrière (AP-HP) Paris France.

出版信息

J Am Heart Assoc. 2020 Apr 7;9(7):e014611. doi: 10.1161/JAHA.119.014611. Epub 2020 Mar 30.

DOI:10.1161/JAHA.119.014611
PMID:32223396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7428610/
Abstract

Background Women have been associated with higher rates of recurrent events after percutaneous coronary intervention than men, possibly attributable to advanced age at presentation and greater comorbidities. These factors also put women at higher risk of bleeding, which may influence therapeutic strategies and clinical outcomes. Methods and Results We performed a patient-level pooled analysis of 4 postapproval registries to evaluate sex-related differences in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention. HBR required fulfillment of at least 1 major or 2 minor criteria of the Academic Research Consortium definition. Outcomes of interest were major bleeding and major adverse cardiac events (composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis). Of the total 10 502 patients, 2832 (27.0%) were women. The prevalence of HBR was higher in women compared with men (29.0% versus 20.5%, <0.0001). Women at HBR were older and had more comorbidities, while men at HBR were more often smokers, with prior myocardial infarction and more complex coronary lesions. At 4 years, women at HBR had significantly higher major bleeding compared with men at HBR (10.8% versus 6.2%, <0.0001); however, this difference was attenuated after multivariable adjustment (hazard ratio, 0.92; 95% CI, 0.41-2.08). Major adverse cardiac event rates between groups were similar (12.2% versus 12.6%, =0.82) and remained consistent after adjustment (hazard ratio, 0.64; 95% CI, 0.32-1.28). Conclusions The prevalence of HBR was higher in women compared with men, with considerable differences in the distribution of criteria. Women at HBR experienced higher rates of major bleeding but similar major adverse cardiac event rates compared with men at HBR at 4 years.

摘要

背景

与男性相比,女性经皮冠状动脉介入治疗后的复发事件发生率更高,这可能归因于发病时年龄较大和合并症较多。这些因素也使女性出血风险更高,这可能会影响治疗策略和临床结局。

方法和结果

我们对 4 项批准后注册研究进行了患者水平的汇总分析,以评估高出血风险(HBR)行经皮冠状动脉介入治疗的患者的性别差异。HBR 需要满足学术研究联合会(ARC)定义的至少 1 项主要标准或 2 项次要标准。主要观察终点为大出血和主要不良心脏事件(包括心脏死亡、心肌梗死或确定/可能的支架血栓形成)。在总共 10502 例患者中,2832 例(27.0%)为女性。与男性相比,女性的 HBR 发生率更高(29.0%比 20.5%,<0.0001)。HBR 女性年龄较大,合并症较多,而 HBR 男性更多为吸烟者,既往有心肌梗死且冠状动脉病变更为复杂。4 年时,HBR 女性的大出血发生率明显高于 HBR 男性(10.8%比 6.2%,<0.0001);然而,经多变量调整后,这种差异减弱(风险比,0.92;95%可信区间,0.41-2.08)。两组之间的主要不良心脏事件发生率相似(12.2%比 12.6%,=0.82),调整后仍保持一致(风险比,0.64;95%可信区间,0.32-1.28)。

结论

与男性相比,女性 HBR 的发生率更高,且标准的分布存在较大差异。HBR 女性的大出血发生率较高,但与 HBR 男性相比,4 年时的主要不良心脏事件发生率相似。

相似文献

1
Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies.经皮冠状动脉介入治疗中高出血风险患者的性别相关差异:4 项批准后研究的患者水平汇总分析。
J Am Heart Assoc. 2020 Apr 7;9(7):e014611. doi: 10.1161/JAHA.119.014611. Epub 2020 Mar 30.
2
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.经皮冠状动脉介入治疗后出血风险、双联抗血小板治疗停药和不良事件:PARIS 注册研究。
Circ Cardiovasc Interv. 2020 Apr;13(4):e008226. doi: 10.1161/CIRCINTERVENTIONS.119.008226. Epub 2020 Mar 27.
3
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.高出血风险患者中持久聚合物钴铬依维莫司洗脱支架的长期安全性和疗效:四项上市后研究的患者水平分层分析。
Circulation. 2020 Mar 17;141(11):891-901. doi: 10.1161/CIRCULATIONAHA.119.041619. Epub 2020 Jan 29.
4
Application of the Academic Research Consortium High Bleeding Risk criteria in patients treated with coronary bioresorbable polymer everolimus-eluting stents: Insights from the POEM trial.应用学术研究联合会高出血风险标准于接受冠状动脉生物可吸收聚合物依维莫司洗脱支架治疗的患者:来自 POEM 试验的结果。
Cardiovasc Revasc Med. 2024 Oct;67:77-83. doi: 10.1016/j.carrev.2024.04.022. Epub 2024 Apr 16.
5
Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.ESC DAPT 指南推荐的高血栓风险特征对 PCI 后高出血风险和低出血风险患者长期临床结局的影响。
BMC Cardiovasc Disord. 2020 Jul 1;20(1):313. doi: 10.1186/s12872-020-01600-3.
6
Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.对于接受经皮冠状动脉介入治疗的高出血风险患者,裸金属支架植入是否仍合理?:来自ZEUS试验的预先指定分析。
JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36. doi: 10.1016/j.jcin.2015.11.015.
7
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).药物洗脱支架经皮冠状动脉介入治疗后高血小板反应性临床影响的性别差异:ADAPT-DES研究(药物洗脱支架双重抗血小板治疗评估)结果
Circ Cardiovasc Interv. 2017 Feb;10(2). doi: 10.1161/CIRCINTERVENTIONS.116.003577.
8
Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study.聚合物涂层冠脉支架高出血风险患者的全球策略:LF II 研究。
Circ Cardiovasc Interv. 2020 Apr;13(4):e008603. doi: 10.1161/CIRCINTERVENTIONS.119.008603. Epub 2020 Apr 13.
9
Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention.学术研究联盟高出血风险标准在经皮冠状动脉介入治疗所有患者登记中的应用。
Circ Cardiovasc Interv. 2019 Nov;12(11):e008307. doi: 10.1161/CIRCINTERVENTIONS.119.008307. Epub 2019 Nov 11.
10
Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.东亚患者经皮冠状动脉介入治疗后血小板反应性与缺血和出血事件的关系:PENDULUM 登记研究的 1 年结果。
J Am Heart Assoc. 2020 May 18;9(10):e015439. doi: 10.1161/JAHA.119.015439. Epub 2020 May 12.

引用本文的文献

1
Sex differences based on the timing of invasive management among patients with non-ST-elevation acute coronary syndrome: an individual patient data meta-analysis.非ST段抬高型急性冠状动脉综合征患者侵入性治疗时机的性别差异:一项个体患者数据荟萃分析
Eur Heart J Open. 2025 May 17;5(3):oeaf059. doi: 10.1093/ehjopen/oeaf059. eCollection 2025 May.
2
Age and sex differences in the efficacy of early invasive strategy for non-ST-elevation acute coronary syndrome: A comparative analysis in stable patients.非ST段抬高型急性冠状动脉综合征早期侵入性策略疗效的年龄和性别差异:稳定患者的比较分析
Am J Prev Cardiol. 2025 Mar 29;22:100984. doi: 10.1016/j.ajpc.2025.100984. eCollection 2025 Jun.
3

本文引用的文献

1
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.定义经皮冠状动脉介入治疗患者的高出血风险:来自高出血风险学术研究联合会的共识文件。
Eur Heart J. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372.
2
Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention.经皮冠状动脉介入治疗患者发生显著院外出血的决定因素。
Thromb Haemost. 2018 Nov;118(11):1997-2005. doi: 10.1055/s-0038-1673687. Epub 2018 Oct 12.
3
Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease.
Sex-based Differences in Complications Following Percutaneous Coronary Interventions.
经皮冠状动脉介入治疗后并发症的性别差异。
Curr Atheroscler Rep. 2025 Feb 17;27(1):33. doi: 10.1007/s11883-025-01278-y.
4
Can Artificial Intelligence Change our Interpretation of Cardiovascular Risk Scores?人工智能能改变我们对心血管风险评分的解读吗?
Arq Bras Cardiol. 2024 Jul 19;121(4):e20240280. doi: 10.36660/abc.20240280.
5
Understanding Differences in Sex-Based Outcomes with Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后双重抗血小板治疗中基于性别的结果差异分析
Drugs. 2024 Jun;84(6):703-705. doi: 10.1007/s40265-024-02041-4. Epub 2024 May 29.
6
Two-year outcomes of endovascular therapy for femoropopliteal arterial lesions for patients with high bleeding risk.高出血风险患者股腘动脉病变血管内治疗的两年结果。
Cardiovasc Interv Ther. 2024 Jul;39(3):284-292. doi: 10.1007/s12928-024-00999-2. Epub 2024 Apr 17.
7
Management of cardiac emergencies in women: a clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the European Heart Rhythm Association (EHRA) of the ESC, and the ESC Working Group on Cardiovascular Pharmacotherapy.女性心脏急症的管理:欧洲心脏病学会急性心血管护理协会(ACVC)、欧洲经皮心血管介入协会(EAPCI)、心力衰竭协会(HFA)、欧洲心律协会(EHRA)以及欧洲心脏病学会心血管药物治疗工作组的临床共识声明
Eur Heart J Open. 2024 Feb 26;4(2):oeae011. doi: 10.1093/ehjopen/oeae011. eCollection 2024 Mar.
8
Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.经皮冠状动脉介入治疗患者双联抗血小板治疗 3 个月后单用 P2Y12 抑制剂的性别结局。
J Korean Med Sci. 2023 Nov 20;38(45):e383. doi: 10.3346/jkms.2023.38.e383.
9
In-hospital major bleeding in patients with acute coronary syndrome medically treated with dual anti-platelet therapy: Associated factors and impact on mortality.接受双联抗血小板治疗的急性冠状动脉综合征患者的院内大出血:相关因素及对死亡率的影响。
Front Cardiovasc Med. 2022 Oct 31;9:878270. doi: 10.3389/fcvm.2022.878270. eCollection 2022.
10
Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?缺血性心脏病全病程抗栓治疗中的性别差异:是时候应对“燕特尔综合征”了?
Front Cardiovasc Med. 2022 Oct 31;9:1009475. doi: 10.3389/fcvm.2022.1009475. eCollection 2022.
与冠心病相关的口服抗血栓药物的获益和风险的性别差异。
Expert Opin Drug Saf. 2018 Oct;17(10):1041-1052. doi: 10.1080/14740338.2018.1524869. Epub 2018 Sep 23.
4
Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan.日本钴铬合金依维莫司洗脱支架(XIENCE V/PROMUS)上市后研究的五年临床结果。
Cardiovasc Interv Ther. 2019 Jan;34(1):40-46. doi: 10.1007/s12928-018-0515-z. Epub 2018 Feb 26.
5
Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial.老年冠心病患者药物洗脱支架的研究(SENIOR):一项随机单盲试验
Lancet. 2018 Jan 6;391(10115):41-50. doi: 10.1016/S0140-6736(17)32713-7. Epub 2017 Nov 1.
6
Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation: Insights and Results From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study Pooled Analysis.依维莫司洗脱支架置入术后 1 年女性和少数民族与白人男性的结局:PLATINUM 多样性和 PROMUS Element Plus 上市后研究汇总分析的见解和结果。
JAMA Cardiol. 2017 Dec 1;2(12):1303-1313. doi: 10.1001/jamacardio.2017.3802.
7
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.非常薄的支撑物可生物降解聚合物依维莫司洗脱和西罗莫司洗脱支架与全人群冠心病使用耐用聚合物佐他莫司洗脱支架(BIO-RESORT):一项三臂、随机、非劣效试验。
Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30.
8
Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.年龄小于55岁的急性冠状动脉综合征患者接受经皮冠状动脉介入治疗后结局的性别差异:普罗米修斯研究结果
Catheter Cardiovasc Interv. 2017 Mar 1;89(4):629-637. doi: 10.1002/ccd.26606. Epub 2016 May 24.
9
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.经药物洗脱支架 PCI 术后的冠状动脉血栓形成和大出血:PARIS 风险评分。
J Am Coll Cardiol. 2016 May 17;67(19):2224-2234. doi: 10.1016/j.jacc.2016.02.064. Epub 2016 Apr 11.
10
Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.对于接受经皮冠状动脉介入治疗的高出血风险患者,裸金属支架植入是否仍合理?:来自ZEUS试验的预先指定分析。
JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36. doi: 10.1016/j.jcin.2015.11.015.